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Abstract In experimental studies, mesenchymal stem cell
(MSC) transplantation in acute myocardial infarction (AMI)
models has been associated with enhanced neovascularization
and myogenesis. Clinical data however, are scarce. Therefore,
the present study evaluates the safety and feasibility of
intramyocardial MSC injection in nine patients, shortly after
AMI during short-term and 5-year follow-up. Periprocedural
safety analysis demonstrated one transient ischemic attack. No
other adverse events related to MSC treatment were observed
during 5-year follow-up. Clinical events were compared to a
nonrandomized control group comprising 45 matched
controls. A 5-year event-free survival after MSC-treatment
was comparable to controls (89 vs. 91 %, P=0.87). Echocar-
diographic imaging for evaluation of left ventricular function
demonstrated improvements up to 5 years after MSC treat-
ment. These findings were not significantly different when
compared to controls. The present safety and feasibility study
suggest that intramyocardial injection of MSC in patients
shortly after AMI is feasible and safe up to 5-year follow-up.
Keywords Mesenchymal stem cells . Clinical stem cell




MSCs Mesenchymal stem cells
LV Left ventricular
PCI Percutaneous coronary intervention
SPECT Single-photon emission computed tomography
Introduction
Despite the use of state-of-the-art invasive and pharmacolog-
ical treatment strategies, myocardial infarction (MI) remains a
major cause of morbidity and mortality worldwide. Over the
last decade, several nonrandomized and randomized studies
have demonstrated that transplantation of bone marrow-
derived cells shortly after acute MI may result in improved
cardiac function and reduced infarct size [1]. Therefore,
cardiac stem and progenitor cell transplantation is currently
under investigation as a potential therapeutic option for
acute MI patients.
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Mesenchymal stem cells (MSCs), a subpopulation of bone
marrow cells, were found to be able to differentiate into
various cell types including vascular cells and, under specific
in vitro conditions, functional cardiomyocytes [2, 3]. In pre-
clinical models of acute MI, MSC transplantation is reported
to promote neovascularization and myogenesis, resulting in
improved myocardial function [2, 4]. Early clinical studies
documented that intracoronary and intravenous infusion of
MSCs shortly after acute MI is safe and feasible [5, 6].
Moreover, a beneficial effect on global and regional left
ventricular (LV) function was presumed. Recently, Williams
et al. suggested that catheter-based intramyocardial MSC in-
jection in patients with chronic ischemic heart disease is safe
and results in a reduced perfusion defect size and an improved
contractility after 12 months [7].
Until now, no clinical study assessed the safety and feasi-
bility of catheter-based intramyocardial MSC injection shortly
after acute MI. Conceptually, intramyocardial injection may
be more suitable for the delivery of large cell types such as
MSCs without the potential risk of micro-embolism formation
as reported after intracoronary delivery of MSCs in dogs [8]
and umbilical cord-derived stem cells in pigs [9]. Further-
more, intramyocardial cell delivery has been associated with
higher retention rate of injected cells as compared to
intracoronary and intravenous infusion [10] culminating in
potential greater beneficial effect on the myocardium.
The aim of the present study was to determine the short-
and long-term safety and feasibility of intramyocardial autolo-
gous bone marrow-derived, ex vivo expanded, MSC injection
in patients shortly (<4 weeks) after acute ST-segment elevation
MI. Furthermore, the effect on cardiac function andmyocardial
perfusion was evaluated at short- and long-term follow-up and
compared to a historical control group.
Methods
Patient Population
Patients with a first acute ST-segment elevation MI treated by
primary percutaneous coronary intervention (PCI) of the
infarct-related coronary artery <12 h after onset of chest pain
were eligible for inclusion in the current study if the maximal
CK level was >1,600 U/L. Exclusion criteria were prior MI
and/or coronary artery bypass grafting, a history of malignan-
cy, the presence of an unstable medical situation, a remaining
significant coronary lesion for which an additional revascu-
larization procedure was warranted, significant co-morbidity
(e.g., renal dysfunction [glomerular filtration rate, <30 ml/
min/1.73 m2], significant valvular heart disease, active infec-
tion), concurrent participation in another study, or unwilling-
ness to participate. The institutional ethical committee ap-
proved the study protocol and written informed consent was
obtained from all patients. The study was registered at the
Dutch trial registry (www.trialregister.nl, no. NTR1553).
Study Protocol
The study protocol of this safety and feasibility study is
displayed in Fig. 1. The baseline evaluation consisted of
two-dimensional (2D) echocardiography (<24–48 h of admis-
sion for acute MI) and stress–rest single-photon emission
computed tomography (SPECT; approximately 2 weeks after
acute MI).
Bone marrow was aspirated from the iliac crest under local
anesthesia within 7 days after the infarction. Following mono-
nuclear cell isolation, the MSCs were expanded ex vivo for
14–24 days, after which the intramyocardial injection proce-
dure was performed. For this purpose, a three-dimensional
electromechanical map of the LV was generated with the use
of the NOGA system (Biologics Delivery Systems Group,
Cordis; Bridgewater, NJ, USA). After completion of the elec-
tromechanical map of the LV, the mapping catheter was re-
placed by an injection catheter (MyoStar catheter, Biosense-
Webstar) and MSC injections were targeted in the infarct
border zone. Subsequently, 8–12 intramyocardial injections
of approximately 0.2–0.5 mL each were performed with the
NOGA system as previously described [11]. After the proce-
dure, continuous heart rhythm monitoring was started for
2 days and laboratory markers of myocardial damage were
collected. To assess potential postprocedural pericardial effu-
sion, echocardiographywas performed 1 day after the injection
procedure.
After discharge, the clinical status was assessed at the
outpatient clinic at 3, 6, and 12 months follow-up. To monitor
the occurrence of ventricular arrhythmias 24-h Holter moni-
toring was performed at 3 and 6 months follow-up. LV func-
tionwas determinedwith the use of 2D echocardiography at 3,
6, and 12 months and myocardial perfusion was assessed at
3 months. After the first year of follow-up, patients were
evaluated at the outpatient clinic on a yearly basis to assess
the occurrence of clinical events (death, MI, revascularization,
and hospitalization for heart failure). At 4–5 year follow-up,
an additional evaluation was performed containing a 24-h
Holter recording and 2D echocardiography. From patients
who died during follow-up, hospital records were reviewed
and the cause of death was ascertained.
Mesenchymal Stem Cell Isolation and Expansion
Ex vivo expansion of mononuclear cells was performed
according to a protocol devised by the European Group for
Blood and BoneMarrowTransplantation developmental com-
mittee, as previously described [12]. In summary, after bone
marrow aspiration, mononuclear cells were isolated by Ficoll
density gradient centrifugation (density, 1.077 g/cm3) and
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were washed and resuspended in Dulbecco’s modified Eagle’s
low-glucose medium (Invitrogen, Paisley, UK) supplemented
with penicillin and streptomycin (Lonza, Verviers, Belgium)
and 10 % fetal bovine serum (HyClone, Logan, UT, USA),
without any additional growth factors. Mononuclear cells
were plated at a density of 160,000 cells/cm2 and cultures
were maintained at 37 °C in a humidified atmosphere con-
taining 5 % CO2 in 175 cm
2 flasks (Greiner Bio-One,
Frickenhausen, Germany). The cells were detached and
replated when the cultures reached near confluence (>80 %).
MSCs were passaged up to a maximum of two times. At the
day of cell injection, the cells were harvested and were
suspended in a 5 mL (or 2.5 mL if final cell count was
<10×106 cells) isotonic buffer with human serum albumin
or human autologous serum and packaged in 2.5 mL syringe
for intramyocardial injection. The expanded cell population
was tested for sterility as well as the presence of mycoplasma
genus by PCR. Culture expanded MSCs were characterized
by morphological examination and immunophenotying using
a panel of membrane markers (HLA-I, HLA-DR, CD 31, CD
34, CD 45, CD 73, CD 80, CD 90, and CD 105).
SPECT Imaging
For SPECT imaging, a previously described 2-day outpatient
stress–rest protocol was used [13]. In brief, during the stress
protocol, adenosine (0.14 mg/kg/min) was infused for 6 min
and 500 MBq Tc-99m tetrofosmin was injected intravenously
after 3.5 min of adenosine. A second injection of 500 MBq
technetium-99m tetrofosmin was performed to obtain resting
images. Myocardial perfusion was analyzed by reconstructing
a standard short- and long-axis projection, perpendicular to
the heart axis, which was adjusted for peak myocardial activity
(100 %).
Myocardial perfusion was analyzed using Quantitative
Gated SPECT software (QGS software, Cedars-Sinai Medical
Center, Los Angeles, CA, USA). The myocardium was divid-
ed into 17 segments and segmental tracer activity was catego-
rized on a four-point scale: 1=tracer activity, >75 %; 2=tracer
activity, 50–75 %; 3=tracer activity, 25–49 %; and 4=tracer
activity, <25 %. Significant fill-in (>10 %) of perfusion de-
fects observed on the images at rest was classified as ischemic
myocardium. The summed stress score and summed rest score
were calculated by summation of the patients’ segmental
scores, respectively, at stress and rest. All measurements were
performed by two experienced observers (J.v.R. and S.F.R),
Echocardiography
Patients were imaged in the left lateral decubitus position
using a commercially available system (Vivid 7 and E9,
General Electric-Vingmed, Horten, Norway). Data acquisition
Fig. 1 Flow chart of patients
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was performed with a 3.5-MHz transducer at a depth of 16 cm
in the standard parasternal and aprical views. During breath
hold, M-mode and 2D images were obtained and saved in
cine-loop format. Data analysis was performed offline
(EchoPAC version 111.0.0; General Electric-Vingmed,).
End-diastolic volumes, end-systolic volumes, and LVejection
fractions were derived from the conventional 2D apical two-
and four-chamber images, using the biplane Simpson’s rule. A
16-segment model of the LV was used to assess regional wall
motion and wall motion score index by a four-point scale
calculation (1=normokinesia, 2=hypokinesia, 3=akinesia,
4=dyskinesia). Previous work has reported on the inter- and
intravariabilities in our laboratory [14].
Historical Control Group
In order to provide more insight in the safety of intramyocardial
MSC injection after acute MI, a historical control group
was included retrospectively consisting of patients with a first
ST-segment elevation acute MI, successfully treated with
primary PCI, during the study period who matched the inclu-
sion and exclusion criteria of the study, but who could not be
included because of logistical reasons. For each patient in-
cluded for MSC treatment, five controls were included that
were matched for age-, gender-, and infarct-related coronary
artery.
Control patients were monitored at the regular post-
infarction outpatient clinic at 3, 6, and 12 months follow-up.
The standardized follow-up of these patients included 2D
echocardiography at 3, 6, and 12 months follow-up (similar
as in MSC-treated patients). After the first year of follow-up,
patients were monitored by either outpatient clinic visits and/or
telephone inquiry [15].
Statistical Analysis
Data are reported as mean±SD. Continuous variables were
compared using a Wilcoxon signed-rank test or Mann–
Whitney test. Categorical data were compared using a Fisher’s
exact test. A Friedman test was applied to analyze echocar-
diographic results of MSC-treated patients at >2 time points.
To compare the change in echocardiographic results during
12 months follow-up between MSC-treated patients and
controls, a two-way repeated measures analysis of variance
was applied. For comparison of echocardiographic re-
sults, a complete case analysis was used. Clinical out-
come was assessed by Kaplan–Meier analysis, for which
only the first event of each patient was included into the
analysis. Differences between event-free survival curves were
tested with the log-rank statistic. A P value <0.05 was con-
sidered statistically significant. All statistical analyses were
performed with SPSS software version 17.0 (SPSS, Chicago,
IL, USA).
Results
Between 2006 and 2008, a total of nine patients (age 56±
8 years) were treated by intramyocardial autologous MSC
injection. The baseline data of these nine patients and the 45
historical controls (age 60±11 years) are summarized Table 1.
As indicated, echocardiographically assessed LVejection frac-
tion was 48±3 % inMSC-treated patients and 44±10% in the
controls (P=0.33).
Mesenchymal Stem Cell Expansion
Bone marrow aspiration resulted in 123±17 ml of bone mar-
row. After 18.6±3.5 days of culturing, the expansion proce-
dure yielded 46±3×106 MSCs with a viability of 93±5 %.
Immunophenotypical characterization of the MSC products
showed expression of HLA-I, CD73, CD90, and CD105
surface molecules and absence of expression for CD34,
Table 1 Baseline characteristics
Controls MSC P value*
Number of patients 45 9
Age (years) 61±11 56±8 0.54
Men 35 (78 %) 7 (78 %) 1.00
Cardiovascular risk factors
Smoking 19 (42 %) 6 (67 %) 0.28
Hypertension 18 (40 %) 4 (44 %) 1.00
Diabetes mellitus 5 (11 %) 1 (11 %) 1.00
Dyslipidemia 9 (20 %) 2 (22 %) 1.00
Family history of coronary
artery disease
18 (40 %) 4 (44 %) 1.00
Laboratory findings during MI admission
Peak troponine T level (μg/L) 10.1±5.6 9.1±6.2 0.62
Peak CK level (μ/L) 4859±3677 3242±1277 0.20
Creatinine kinase (U/L) 75±12 85±30 0.30
Infarct-related coronary artery
Right coronary artery 15 (33 %) 3 (33 %) 1.00
Left anterior descending 25 (56 %) 5 (56 %)
Left circumflex 5 (11 %) 1 (11 %)
Medication at dischargea
Aspirin 42 (93 %) 6 (67 %) <0.05
Clopidogrel 43 (100 %) 9 (100 %) 1.00
Oral anticoagulant 1 (2 %) 3 (33 %) <0.05
ACE/AT2 43 (100 %) 9 (100 %) 1.00
Statin 43 (100 %) 9 (100 %) 1.00
Beta-blocker 43 (100 %) 9 (100 %) 1.00
CK creatine kinase, ACE angiotensin converting enzyme inhibitor, AT2
angiotensin receptor blocker
a Two controls died during admission
*P values are given for the comparison of controls versus MSC-treated
patients
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CD45, CD31, CD80, and HLA DR (data not shown) in
compliance with the definition of MSC by the International
Society for Cellular Therapy [16]. Injected per patient was
31±2×106 MSCs (Table 2).
Periprocedural Data
Intramyocardial MSC injection was performed 21±3 days
after infarction. Mean procedural time for LV mapping and
cell injection was 71±23 min. Patients received a mean of
11±1 intramyocardial injections.
One patient experienced a transient ischemic attack 2 h
after the injection procedure and developed a recurrence of
atrial fibrillation during this transient ischemic attack that was
successfully treated by electrical cardioversion. During hospi-
talization, repetitive laboratory measurements revealed no
postprocedural MI or systemic inflammation. In addition,
sustained ventricular tachycardias were not observed and 2D
echocardiography did not reveal pericardial effusion. All pa-
tients were discharged 48 h after the injection procedure.
Safety Data of MSC Injection
During the study period, one patient died at 9 months follow-
up due to postoperative infectious complications after a surgi-
cal LV reconstruction, mitral, and tricuspid valve annuloplasty
which was performed because of progressive heart failure and
LV dysfunction. This serious adverse event was considered not
to be related to the MSC therapy. In summary, this diabetic
patient had a large anterior MI with an 11-h delay to PCI. Prior
to the injection procedure, echocardiography had shown a
developing apical aneurysm for which the patient was started
on oral anticoagulant treatment. During follow-up after cell
injection, the patient experienced increasing heart failure relat-
ed complaints, up to New York Heart Association class III/IV,
with an LV ejection fraction that gradually decreased from
43 % at baseline to 17 % at the time of surgery. Microscopic
evaluation of myocardial samples obtained at autopsy did not
reveal any calcification or osteoid depositions. Furthermore,
the von Kossa staining, used to quantify mineralization in
tissue, could not demonstrate any calcium depositions in the
myocardium.
Throughout the study period, none of the patients experi-
enced a recurrent MI. In two patients, a PCI was performed at
4 months respectively 4 years of follow-up because of pro-
gressive stable angina pectoris both due to a new stenosis of a
nonculprit coronary artery located outside the MSC-injected
area of the myocardium. For this reason, these events were
also considered not to be related to the MSC injection.
Repeated Holter monitoring revealed no ventricular ar-
rhythmias during the 4–5 year follow-up period. Of interest,
at long-term follow-up, none of the patients had symptoms or
signs of heart failure.
Long-Term Follow-up in MSC-Treated Patients
and Historical Controls
At 4–5 year follow-up, the survival was similar between
MSC-treated patients and historical controls (89 vs. 89 %,
P=0.97). Furthermore, the percentage of major coronary
events (MI or revascularization procedures) was comparable
in both groups (22 vs. 18 %, P=0.88). The Kaplan–Meier
curves of event-free survival for death, MI, revascularization,
and admission for heart failure are shown in Fig. 2.
Myocardial Perfusion Assessed by SPECT
Paired SPECT studies were available for all nine MSC-treated
patients at 3 months follow-up. As shown in Fig. 3, the
summed stress score improved from 33±7 at baseline to 30±
7 at 3 months (P <0.01). Similarly, the summed rest score
improved from 31±8 to 29±8 at 3 months (P=0.04). The
number of ischemic segments significantly decreased from
1.6±1.9 to 0.7±1.4 at 3 months (P=0.02).
Echocardiography
Echocardiography at baseline and 3, 6, and 12 months follow-
up was available in eight MSC-treated patients and in 38
control patients. Table 3 displays the results of LV function
assessment during the follow-up period. In MSC-treated pa-
tients, there was an improvement in LVejection fraction from
48±2 % at baseline to 52±2 % at 3 months and 57±3 % at
12 months (P <0.01). The magnitude of improvement is sim-
ilar to the improvement observed in historical controls (Fig. 4;
P=0.28).
Echocardiography at long-term follow-up (4.3±1.3 years)
was available in eight MSC-treated patients and revealed that
the improvement in LV ejection fraction was sustained
(55±7 %, P=0.41 vs. 12 months). Table 2 displays the results
of LV function assessment during follow-up of individual
MSC-treated patients.
Discussion
The present study is the first clinical trial to evaluate the feasi-
bility and long-term (up to 5 years) safety of intramyocardial
injection of bone marrow-derived, ex vivo-expanded MSCs
shortly after acute MI. The main finding from the current study
is that MSC treatment is feasible and safe at short term and up to
5 years of follow-up. Furthermore, the 5-year event-free survival
was not different from the control group. Global LV function
assessed by echocardiography showed continuous improve-
ments in LV systolic function after MSC injection during the
first 12 months that were comparable to the control group and
which were maintained up to 5 years post-MI.
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Bone marrow-derived MSCs are a promising cell type for
cell-based therapy. In preclinical studies, MSC transplantation
resulted in improved LV function, increased capillary density
and reduced infarct size in models of acute MI [2, 17, 18].
Since in vivo differentiation of naive MSCs into new
cardiomyocytes remains controversial [19], these beneficial
effects are most likely related to stimulation of angiogenesis
by differentiation ofMSCs into endothelial and smooth muscle
cells [2, 4] and by paracrine mechanisms, including secretion
of a variety of growth factors and cytokines that contribute to
cardiac repair. Interestingly, MSCs also have the ability to
home to sites of acute tissue injury [20], the potential to
actively suppress the immune system and reduce inflammation
[21, 22], and thereby possibly inducing repair and contributing
to functional improvement after acute MI.
Although bone marrow aspiration is well tolerated, culture
times from 2 to 5 weeks prohibit the acute therapeutic use of
autologous bone marrow-derived MSCs. Precultured and
cryopreserved allogeneic MSCs might be considered as
alternative in this respect. Allogeneic bone marrow MSC,
however, might be liable for immune rejection [23, 24], while
both autologous and allogeneic bone marrow MSCs require
dedicated staff and certified culturing facilities which can be
logistically challenging. Although these bone marrow MSC
associated hurdles might be addressed using bioreactors [25],
autologous adipose tissue-derived cell (ADSCs) therapy is
presently investigated as a promising alternative. ADSCs
can be harvested in large amounts without a need for further
culturing and have been demonstrated to express similar sur-
face markers and a comparable self-renewal and differentia-
tion capacity as bone marrow-derived MSCs [26, 27]. Pre-
clinical studies demonstrated beneficial effects on LV function
and myocardial perfusion after transplantation of ADSCs in
acute MI models [28, 29] and the first-in-men safety and
feasibility study is currently underway [26].
Clinical experience withMSCs for cardiac cell therapy after
acute MI is limited, comprising a number of small-sized clin-
ical studies in which different administration routes have been
used [5, 6, 30]. For example, in a clinical trial performed by
Chen et al. which randomized patients with acute MI to
intracoronary infusion of autologous MSCs or placebo, MSC
treatment was associated with beneficial effects on LV function
and myocardial perfusion [5]. In another randomized trial by
Hare et al., intravenous infusion of allogeneicMSCs in patients
with acute MI resulted in improved LV systolic function after
cell treatment in a subgroup of anterior MI patients as com-
pared to placebo [6]. Importantly, the abovementioned studies
did not document serious MSC-related adverse events but the
follow-up was limited to 6 months.
The current study is the first study using the intramyocardial
injection technique for MSC delivery in patients with acute
MI. Catheter-based transendocardial injection of bonemarrow-
derived cells has been performed in several studies in patients
with chronic MI or refractory angina [7, 11, 31, 32], which
demonstrated that this technique is feasible and safe, also
after long-term follow-up. An advantage of this technique is
that viability of potential injection sites can be assessed,
allowing accurate targeting of cell injections into the infarct
border zone or ischemic myocardium [33, 34]. Furthermore,
intramyocardial injection is suggested to result in higher rates
of cell retention as compared to intracoronary or intravenous
infusion [35], possibly culminating in a larger functional
improvement [36]. Finally, intramyocardial injection avoids
the potential risk of coronary obstruction and microinfarction,
which is considered to be a risk of intracoronary MSC infu-
sion [8]. Trans-endocardial injection procedures on the
other hand might theoretically be less safe in recently
infarcted myocardium. The unremarkable short and long
follow-up in our patients however indicates the safety of
the transendocardial injection procedure. Specifically, no ma-
lignant arrhythmias occurred during or after the procedure and
no pericardial effusion was observed on echocardiography
Fig. 2 Kaplan–Meier curve for event-free survival of death, MI, revas-
cularization and admission for heart failure. Event-free survival at 5 years
follow-up was comparable between MSC-treated patients and controls
(P=0.97)
Fig. 3 Individual improvements in segmental perfusion during exercise
and rest after 3 months follow-up. Patients treated with MSCs showed a
significant improvement in summed stress score (P<0.01) and summed
rest score (P=0.04) when compared to baseline
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1 day after the injection procedure. In agreement, no events
were observed in a recent study on 20 patients during
12 months follow-up of trans-endocardial bone marrow-
derived mononuclear cell injection in patient shortly after
acute MI [37].
In previous trials, safety of MSC administration has been
reported up to 12 months follow-up [7]. The current study is
the first to report safety results up to 5 years after MSC
administration. Importantly, the event-free survival was not
different between MSC-treated patients and the control group
and no adverse events related to MSC treatment were ob-
served. During follow-up, 24-h Holter monitoring revealed
no ventricular arrhythmias and echocardiography did not de-
tect any myocardial tumor formation. However, one patient
gradually developed therapy resistant heart failure and died
9 months after MSC injection as a result of a septic shock
during a prolonged ICU stay following extensive heart failure
surgery. Although the cause of death is not MSC-related, an
MSC-related progression of the heart failure cannot be ruled
out. Histological examination of the myocardium of this pa-
tient revealed no evidence for calcification or osteoid deposi-
tions in the myocardium. Furthermore, this diabetic patient
had a large anterior MI with an 11-h delay to PCI, which are
established risk factors for the development of extensive LV
remodeling [38].
Evaluation of LV function by echocardiography did not
demonstrate significant additional improvements in LV func-
tion in MSC-treated patients as compared to medically treated
control patients in the first 12 months follow-up. Obviously,
given the small number of MSC-treated patients, the study is
not powered to detect a treatment effect on LV function. Also,
the use of serial magnetic imaging rather than echocardiogra-
phy is more suitable to detect small improvements in LV
volumes [39]. Nonetheless, from a safety point of view, the
results from echocardiography during the first 12 months and
at long-term follow-up demonstrate that MSC injection is not
associated with detrimental effects on LV systolic function.
SPECT imaging revealed an improvement in myocardial per-
fusion during rest and exercise 3 months after MSC injection.
However, since SPECT imaging was not repeated in the
control group, the effect of MSC treatment on myocardial
perfusion can therefore not be evaluated.
Study Limitations
The current study has several limitations. Most important,
small relative risks of MSC therapy will not be observed in
the limited number of with MSC-treated patients. Moreover,
the comparison with a matched but nonrandomized control
group is not ideal and liable for confounding. Besides this
general limitation of the control group, functional data for LV
functionality for both controls and treated patients showed to
be similarly improved at 12 months follow-up.
Conclusion
In summary, the results of the current safety and feasibility
study demonstrates that intramyocardial injection of autolo-
gous bone marrow-derived, ex vivo expanded, MSCs in
Table 3 Echocardiographic parameters during follow-up



















LVESV (mL) 50±9 58±18 0.21 49±14 58±22 47±11 54±23 45±14 52±26 0.87
LVEDV (mL) 95±16 105±29 0.36 101±26 112±28 102±20 110±24 104±30 108±28 0.46
LVEF (%) 48±2 45±9 0.38 52±2 49±11 54±4 50±10 57±3 50±12 0.28
WMSI 1.6±0.2 1.7±0.3 0.28 1.4±0.3 1.5±0.3 1.4±0.5 1.4±0.3 1.2±0.1 1.4±0.3 0.20
LVESV left ventricular end-systolic volumes, LVEDV left ventricular end-diastolic volumes, LVEF left ventricular ejection fractions,WMSI WallMotion
Score Index, FU follow-up
*P values are given for the comparison of parameters between controls and MSC-treated patients at baseline
**P values are given for the comparison of parameters between controls and MSC-treated patients during 12 months follow-up
Fig. 4 LV ejection fraction during follow-up for MSC-treated patients
and controls. MSC-treated patients demonstrated a significant improve-
ment in LV ejection fraction during 12 months follow-up (from 48±2 to
57±3 %) that was comparable to controls (45±9 to 50±12%;ΔP=0.28)
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patients shortly after acute MI is feasible and safe at short- and
long-term (up to 5 years) follow-up. Based on the safety
results of the current study and the promising preclinical
findings, we feel that further randomized, placebo-controlled
trials are justified to assess the efficacy of intramyocardial
MSC injection in acute MI patients.
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